Yüklüyor......
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
BACKGROUND: Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the mechanisms of acquired drug resistance to osimertinib have not as yet been clar...
Kaydedildi:
| Yayımlandı: | Thorac Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley & Sons Australia, Ltd
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8169289/ https://ncbi.nlm.nih.gov/pubmed/33939301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13943 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|